Arrowhead posts EAS case report on plozasiran use in FCS pregnancy

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

ARWR

0.00
  • Arrowhead published an EAS 2026 case report on plozasiran use in a pregnant woman with familial chylomicronemia syndrome.
  • Report described sustained triglyceride lowering through pregnancy following preconception dosing, consistent with the drug’s prolonged ApoC3 inhibition effect.
  • No maternal or fetal adverse events were reported. No acute pancreatitis episodes occurred during pregnancy.
  • Full-term infant was delivered with normal APGAR. Birth weight was 3.2 kg. Length was 50 cm.
  • Document cautioned pregnancy exposure data remain insufficient to establish plozasiran safety or efficacy during pregnancy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.